Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
To assess the effectiveness and safety of utidelone injection in patients with advanced or metastatic NSCLC as a phase II trial
Advanced Non-small Cell Lung Cancer
DRUG: utidelone injection
Tumor response to utidelone treatment, Reflected by percentage of tumor size reduction or regression, assessed by imaging techniques and expressed as Objective Response Rate (ORR）ORR is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR) according to RECIST. 1.1., 6 months from first study treatment
Progression free survival (PFS), PFS is defined as the duration of time from first study treatment to disease progression or death from any cause as documented by the investigator, 1 year from first study treatment|Overall survival (OS), OS is defined as the duration of time from first study treatment until death from any cause., 2 year from enrolment|Incidence of treatment-emergent adverse events based the Common Terminology Criteria for Adverse Events (CTCAE) version 4·03, Observe and record incidence of adverse events and severe adverse events associated with utidelone treatment, assessed by investigators according to CTCAE version 4·03, 1 year from first study treatment
To assess the effectiveness and safety of utidelone injection in patients with advanced or metastatic NSCLC as a phase II trial